Cogent Biosciences Business Summary

Cogent Biosciences, Inc. (COGT) is a biotechnology company transitioning from a clinical-stage developer to a fully integrated commercial-stage entity, with a business model centered on the proprietary development and commercialization of precision therapies for genetically defined diseases. The company’s primary revenue potential is driven by its lead asset, bezuclastinib, a highly selective tyrosine kinase inhibitor targeting KIT-mutant driven diseases, including Systemic Mastocytosis (SM) and Gastrointestinal Stromal Tumors (GIST). As of March 2026, Cogent is executing a multi-indication launch strategy following the submission of New Drug Applications (NDAs) for Non-Advanced SM, Advanced SM, and second-line GIST. The company operates through a single business segment focused on its precision oncology and hematology pipeline, which includes internally discovered inhibitors for FGFR2/3, pan-KRAS, and JAK2 V617F. Cogent competes directly with Blueprint Medicines (Ayvakit) and oncology-focused firms like Revolution Medicines, BridgeBio, and Deciphera (Ono Pharmaceutical), positioning itself as a provider of best-in-class selective therapies with superior safety and efficacy profiles compared to first-generation KIT inhibitors. Led by President and CEO Andrew Robbins, who previously served as COO at Array BioPharma and played a pivotal role in the development of Braftovi and Mektovi, the executive team includes Chief Medical Officer Jessica Sachs, MD, Chief Technology Officer Brad Barnett, and Chief Scientific Officer John Robinson, PhD. The company was founded in 2014 by Charles Wilson, PhD (originally as Unum Therapeutics), and has since undergone a strategic pivot toward precision small molecules. Cogent is backed by a robust roster of institutional investors and board members, including Peter Harwin of Fairmount Funds Management, and maintains significant positions from Fidelity (Fmr Llc), BlackRock, Vanguard, and Deerfield Management. The leadership team is further bolstered by recent commercial appointments, such as Senior Vice President of Sales Abb Hayden, to support the anticipated 2H 2026 commercial launch of bezuclastinib, supported by a cash runway extending into 2028.